| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
We investigated level of vascular endothelial growth factor A - 165b (VEGFA-165b) which has been reported to be anti-angiogenic, in the anterior chanber of eyes with age related macular degeneration (AMD) and retinal vein occlusion (RVO). The level of VEGFA-165b in AMD was similar to that in controls suggesting the role of anti-angiogenic isoform of VEGF is not very important in AMD. On the other hand, the level of VEGFA-165b was low in eyes with RVO. We suggest the anti-angiogenic effect by VEGFA-165b is less in the eyes RVO and there is a pro-angiogenic shif of VEGF in RVO.
The experimental choroidal neovascularization model induced by 13(S)-HpODE was reduced by intravitreal injection of human reconbinant VEGFA-165b but the effect was limited.
|
